Dutch pulmonary hypertension expert Prof. Dr. Harm Jan Bogaard delves into the intricacies of the condition in a Spotify podcast for “De Internist”, May 21, 2024

Prof. Dr. Harm Jan Bogaard, pulmonologist and Professor of Experimental Pulmonary Medicine from the Amsterdam UMC deconstructs the underlying mechanisms, risk factors, and symptoms of pulmonary hypertension, as well as shedding light on its diagnosis and management strategies, in a Spotify podcast for De Internist. One hour listening time, well worth it! Tune in at […]

Dutch pulmonary hypertension expert Prof. Dr. Harm Jan Bogaard delves into the intricacies of the condition in a Spotify podcast for “De Internist”, May 21, 2024 Read Post »

According to research presented at the American Thoracic Society (ATS) congress hormone replacement therapy may be associated with improved pulmonary hypertension in women

Interesting news from American Thoracic Society congress 2024, taking place May 17-22 in San Diego, USA. According to research presented at the congress the use of hormone replacement therapy (HRT) may be associated with improved pulmonary hypertension in women. The study included 742 women from all five World Health Organization pulmonary hypertension groups. Audriana Hurbon MD is the

According to research presented at the American Thoracic Society (ATS) congress hormone replacement therapy may be associated with improved pulmonary hypertension in women Read Post »

Patients as teachers? A pilot experiment of patient-led online learning modules for HCPs in Canada proves the effectiveness of this approach, “BMC Medical Education”, May 10, 2024

A study titled “Patients as teachers: a within-subjects randomized pilot experiment of patient-led online learning modules for health professionals” was published on BMC Education on May 10, 2024. Medical education programs are increasingly including presentations by individuals with lived experiences. The authors of the article say that relying on a limited number of speakers may

Patients as teachers? A pilot experiment of patient-led online learning modules for HCPs in Canada proves the effectiveness of this approach, “BMC Medical Education”, May 10, 2024 Read Post »

Is there a role for calcium channel blockers in the contemporary treatment paradigm for pulmonary arterial hypertension? – Lewis Rubin, Circulation, May 13, 2024

“Is There a Role for Calcium Channel Blockers in the Contemporary Treatment Paradigm for Pulmonary Arterial Hypertension?” This is the title of an editorial by Lewis Rubin in Circulation, the journal of the American Heart Association, dated May 13, 2024. Among patients with pulmonary arterial hypertension (PAH), acute vasoreactivity testing during right heart catheterization may

Is there a role for calcium channel blockers in the contemporary treatment paradigm for pulmonary arterial hypertension? – Lewis Rubin, Circulation, May 13, 2024 Read Post »

Can dietary changes treat pulmonary hypertension? A new study suggests that some foods may affect blood vessel stiffening in pulmonary hypertension

The Cell metabolism journal has published a study by the University of Pittsburgh researcher Stephen Chan, MD, PhD, and colleagues from the team of Thomas Bertero at the Université Côte d’Azur in France, which explores the relation between diet and pulmonary hypertension. The findings reveal that hypertensive pulmonary blood vessel cells have an “appetite” for two

Can dietary changes treat pulmonary hypertension? A new study suggests that some foods may affect blood vessel stiffening in pulmonary hypertension Read Post »

PHA Europe celebrates World Pulmonary Hypertension Day 2024 with a webinar on non pulmonary arterial hypertension forms of pulmonary hypertension

PHA Europe, the European Pulmonary Hypertension Association, is celebrating this year’s World Pulmonary Hypertension Day with a webinar on non pulmonary arterial hypertension forms of pulmonary hypertension, featuring world renowned expert expert Ardeschir Ghofrani as keynote speaker.  May 5, 2024 – 16:00 CET Link: https://belaircenter.info/

PHA Europe celebrates World Pulmonary Hypertension Day 2024 with a webinar on non pulmonary arterial hypertension forms of pulmonary hypertension Read Post »

April 28 is ESOT, European Society for Organ Transplantation, Action Day, an annual observance which calls for enhanced cooperation between EU member states to address inequalities in transplantation

April 28 is ESOT – European Society for Organ Transplantation Action Day. ESOT is calling for enhanced cooperation among EU member states to empower transplant centres in delivering consistent, high-quality transplantation service ahead of the EU elections. ESOT is looking to drive the following 5 actions in the European Parliament between 2024 and 2029: Read

April 28 is ESOT, European Society for Organ Transplantation, Action Day, an annual observance which calls for enhanced cooperation between EU member states to address inequalities in transplantation Read Post »

A groundbreaking medical innovation known as the “sentinel skin flap” may hold the key to early detection of rejection in lung transplant patients

Could a medical innovation known as the “sentinel skin flap” hold the key to early detection of rejection in lung transplant patients? This pioneering technique, currently under investigation in a trial conducted by the University of Oxford and NHS Blood and Transplant, offers new hope for enhancing post-transplant care. Leading the charge in this groundbreaking trial is Henk Giele,

A groundbreaking medical innovation known as the “sentinel skin flap” may hold the key to early detection of rejection in lung transplant patients Read Post »

The Fundación Contra la Hipertensión Pulmonar, Spain, has won an important prize for its project on non-invasive remote monitoring for children with pulmonary hypertension

The Spanish Foundation for Pulmonary Hypertension, Fundación Contra la Hipertensión Pulmonar, has been selected as winner of one of the prizes of the “Inocente Foundation” for its project on “Non-invasive Remote Monitoring for children with Pulmonary Hypertension”, which will be carried out at the Ramón y Cajal University Hospital.

The Fundación Contra la Hipertensión Pulmonar, Spain, has won an important prize for its project on non-invasive remote monitoring for children with pulmonary hypertension Read Post »

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin Application n° US17072430, December 12, 2023, Publication Number: US11839631B2. The news was reported in the Magazine “Pharmaceutical Technology, April 4, 2024. To be followed! Read more at this link on the

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin Read Post »

Driving innovation and patient-centred care in pulmonary hypertension: the inspiring journey of Dr. Joanna Pepke-Zaba, March 28, 2024

Dr. Joanna Pepke-Zaba, renowned consultant respiratory physician at Royal Papworth Hospital, recently received a prestigious European Respiratory Society (ERS) lifetime achievement award, marking another milestone in her illustrious career. In an interview with Saša Janković, recently published on March 18, 2024 on “Hospital Health Care Europe”, Dr. Pepke-Zaba discusses her dedication to advancing research and

Driving innovation and patient-centred care in pulmonary hypertension: the inspiring journey of Dr. Joanna Pepke-Zaba, March 28, 2024 Read Post »

Outsanding scientific program for the French Pulmonary Hypertension Association’s Annual General Assembly, April 6 2024

The Annual General Assembly of the French Pulmonary Hypertension Association HTaPFrance is taking place in Paris on Saturday the 6th of April 2024 in Paris. The morning program is dedicated to the presentation of the annual report of activities, vote on financial report and approval of new members of the Board. The afternoon program features

Outsanding scientific program for the French Pulmonary Hypertension Association’s Annual General Assembly, April 6 2024 Read Post »

The US Food and Drug Administration, FDA, approves sotatercept, Merck’s new drug for pulmonary arterial hypertension, March 26, 2024

The US Food and Drug Administration has approved sotatercept, Merck‘s new drug for pulmonary arterial hypertension. It’s commercial name is Winrevair. Read more on the FDA website at this link Sotatercept is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein. It was evaluated as an add-on to stable background therapy for the treatment of pulmonary

The US Food and Drug Administration, FDA, approves sotatercept, Merck’s new drug for pulmonary arterial hypertension, March 26, 2024 Read Post »

Proud and honoured to introduce the Alliance for Pulmonary Hypertension’s Scientific Committee

The Alliance for Pulmonary Hypertension is very honoured to present its Scientific Committee, featuring some of the world’s most renowned experts in the field of pulmonary hypertension. The Scientific Committee will play a pivotal role in supporting the Alliance’s mission to share knowledge and expertise about pulmonary hypertension via its Pulmonary Hypertension Knowledge Sharing Platform.

Proud and honoured to introduce the Alliance for Pulmonary Hypertension’s Scientific Committee Read Post »

Gas-filled balloon implanted in main pulmonary artery to alleviate right ventricle workload tested in pulmonary hypertension

The Aria CV Pulmonary Hypertension System is an implantable gas-filled balloon that is introduced percutaneously in the main pulmonary artery to alleviate the excessive workload on the right heart that results in right heart failure. An article published in the European Journal of Heart Failure on March 13, 2024 titled “Efficacy and safety of the

Gas-filled balloon implanted in main pulmonary artery to alleviate right ventricle workload tested in pulmonary hypertension Read Post »

John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease, London, March 15-16, 2024

The first John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease was held in London, UK, 2006 to honour the memory of Sir John Vane, the founder of the William Harvey Research Institute and Nobel prize Laureate for his discovery of prostacyclin and its analogues (see also our article at this link). It

John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease, London, March 15-16, 2024 Read Post »

Multinational real-world survey offers insights into key factors in delays to diagnosis for pulmonary arterial hypertension patients, Therapeutic Advances in Respiratory Disease, February 2024

Delays to diagnosis in pulmonary arterial hypertension still persist today, despite the substantial progress made in the field. This ongoing issue continues to pose a significant challenge, highlighting the need for continued efforts to improve early detection and intervention strategies. Delays in diagnosis not only prolong patient suffering but also lead to missed opportunities for

Multinational real-world survey offers insights into key factors in delays to diagnosis for pulmonary arterial hypertension patients, Therapeutic Advances in Respiratory Disease, February 2024 Read Post »

Launched today, Rare Disease Day 2024, the PHA Europe “BEL AIR” virtual conference center for pulmonary hypertension

The BEL AIR CENTER is a virtual conference center, divided into several “rooms” where visitors can find and view presentations from leading pulmonary hypertension experts and from PHA Europe’s industry partners, patient association information booths, an art gallery with works by patients and health care professionals, and a networking café. Prof. Marc Humbert, Director of

Launched today, Rare Disease Day 2024, the PHA Europe “BEL AIR” virtual conference center for pulmonary hypertension Read Post »

Coming up soon, the World Symposium on Pulmonary Hypertension 2024, the most important scientific event in the world this field!

The 7th edition of the World Symposium on Pulmonary Hypertension is being held on June 29-30/July 1, 2024, in Barcelona, Spain. The WSPH is the most important scientific event in the field of pulmonary hypertension. It has been convened every five years since the Evian edition in 1998 (including Venice 2003, Dana Point 2008, Nice

Coming up soon, the World Symposium on Pulmonary Hypertension 2024, the most important scientific event in the world this field! Read Post »

TRANSLATE »
Scroll to Top